About

Transforming America’s Access to Essential Medicines

Bright Path Laboratories is a pharmaceutical company committed to changing the way American medicine is sourced and manufactured. Bright Path’s network of advanced manufacturing facilities is based entirely in the United States. Using a continuous flow platform and our patented Spinning-Tube-in-Tube (STT) Reactor™, our process produces large quantities of medicine in less time, at less cost, and with higher quality than our competitors. Our commitment to sustainable Green Chemistry decreases process steps, generates less waste, and uses fewer resources than traditional techniques. With Bright Path, a greener, cleaner, and faster approach to making medicine has finally arrived.

America’s access to medicine is under threat.

Traditional Supply Chains Have Fractured
The reliable flow of essential medicines into the U.S. has been irrevocably ruptured by the Covid-19 pandemic.
Outdated Manufacturing Techniques Have Caused Damage
The batch manufacturing practices widely used today devastate the environment and increase our reliance on foreign sources.
Drug Safety and Quality Have Been Compromised
The use of cheap and toxic additives lowers the efficacy of our medicines and jeopardizes the welfare of consumers.

Bright Path is committed to creating a secure and sustainable supply chain that provides every patient with access to safe and affordable medicines.

Board of Directors

Tony Quinones

Chairman

Michael A. Gonzalez, PhD

Chief Scientific Officer

Phil Lichtenberger

Todd Smith

John LaLonde

Marc Fasteau

Brian Walzer, MD

XiPing Su

Leadership Team

Tony Quiñones

CEO

Tony Quiñones brings 20+ years of experience in entrepreneurship, venture capital investing, and building operating teams with key expertise in commercializing continuous flow manufacturing platform technologies, such as Bright Path Labs Inc.